<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31492197</article-id><article-id pub-id-type="pmc">6728955</article-id><article-id pub-id-type="publisher-id">2586</article-id><article-id pub-id-type="doi">10.1186/s13054-019-2586-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Neuromuscular blocking agents for acute respiratory distress syndrome: how did we get conflicting results?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1961-4104</contrib-id><name><surname>Torbic</surname><given-names>Heather</given-names></name><address><phone>(216) 444-1756</phone><email>torbich@ccf.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Krishnan</surname><given-names>Sudhir</given-names></name><address><email>krishns2@ccf.org</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Duggal</surname><given-names>Abhijit</given-names></name><address><email>duggala2@ccf.org</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0675 4725</institution-id><institution-id institution-id-type="GRID">grid.239578.2</institution-id><institution>Department of Pharmacy, </institution><institution>Cleveland Clinic, </institution></institution-wrap>9500 Euclid Avenue, Hb-105, Cleveland, OH 44195 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0675 4725</institution-id><institution-id institution-id-type="GRID">grid.239578.2</institution-id><institution>Department of Critical Care, </institution><institution>Respiratory Institute, Cleveland Clinic, </institution></institution-wrap>9500 Euclid Avenue, L2-330, Cleveland, OH 44195 USA </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>23</volume><elocation-id>305</elocation-id><history><date date-type="received"><day>10</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par1">Letter</p><p id="Par2">Except for neuromuscular blocking agents (NMBAs), pharmacologic therapies studied for ARDS have not demonstrated mortality benefit. By improving ventilator synchrony, NMBAs reduce ventilator-induced lung injury (VILI) and aid in lung recruitment, thereby improving oxygenation. NMBAs exert their benefit in ARDS by decreasing systemic inflammation and improving V/Q mismatch [<xref ref-type="bibr" rid="CR1">1</xref>]. The seminal trial, ACURASYS, evaluated the use of NMBAs for early, moderate-severe ARDS. It reported an adjusted 90-day mortality benefit of 9.1% with a reduction in the incidence of VILI in patients with a PaO<sub>2</sub>/FiO<sub>2</sub>&#x02009;&#x0003c;&#x02009;120 [<xref ref-type="bibr" rid="CR2">2</xref>]. Despite these findings, enthusiasm for NMBA use in ARDS remained lackluster [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par3">To dispel the concerns associated with adoption of NMBAs, the recently published ROSE trial evaluated the use of NMBAs for early, moderate-severe ARDS. It reported no difference in 90-day mortality or incidence of VILI [<xref ref-type="bibr" rid="CR4">4</xref>]. The conflicting results of the two major trials bring to question the role of NMBAs in the management of ARDS.</p><p id="Par4">The divergent results could be accounted for by various factors (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). First, ARDS was defined differently in both trials. Although patients were enrolled with PaO<sub>2</sub>/FiO<sub>2</sub>&#x02009;&#x0003c;&#x02009;150&#x02009;mmHg, ROSE patients had a higher baseline PEEP (&#x02265;&#x02009;8&#x02009;cm&#x02009;H<sub>2</sub>O). Second, patients were enrolled 8&#x02009;h earlier in ROSE [8(4&#x02013;16) vs. 16(6&#x02013;29)&#x02009;h] [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Patients who would have been excluded from ACURASYS (those who rapidly improved before randomization) were likely included in ROSE limiting the trial&#x02019;s effect. Third, both non-pharmacologic and pharmacologic management was different. Patients in both arms of ACURASYS were deeply sedated, whereas only patients in the treatment arm of ROSE were deeply sedated. Deep sedation, especially in early ARDS, is associated with reverse triggering, which can result in breath stacking, VILI, and increased mortality. Reverse triggering and increased risk of ICU delirium, with decreased time to extubation secondary to deep sedation, may have resulted in higher mortality in the control arm in ACURASYS compared to those in the control arm of ROSE with lighter sedation targets [<xref ref-type="bibr" rid="CR5">5</xref>]. Finally, both studies protocolized ventilator management and lung protective strategies. However, patients in ROSE received lower FiO<sub>2</sub>, but higher PEEP and lower tidal volumes in both study arms, probably improving lung recruitment and decreasing atelectrauma [<xref ref-type="bibr" rid="CR5">5</xref>].
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Differences between ACURASYS and ROSE trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>ACURASYS (2)</th><th>ROSE (4)</th></tr></thead><tbody><tr><td>ARDS definition</td><td>-AECC</td><td>-Berlin</td></tr><tr><td>Median time to enrollment from ARDS diagnosis</td><td>-16 (6&#x02013;29) vs. 18 (6&#x02013;31) h</td><td>-8.2 (4.0&#x02013;16.4) vs. 6.8 (3.3&#x02013;14.5) h</td></tr><tr><td>Sedation targets</td><td>-Control arm&#x02014;goal Ramsay score 6 (deep sedation)</td><td>-Control arm&#x02014;goal Ramsay score 2&#x02013;3 (light sedation)</td></tr><tr><td>Ventilator strategies</td><td><p>-TV 6&#x02013;8&#x02009;ml/kg</p><p>-Low PEEP (&#x02265;&#x02009;5&#x02009;cm H<sub>2</sub>O)</p></td><td><p>-TV 6&#x02009;ml/kg</p><p>-High PEEP (&#x02265;&#x02009;8&#x02009;cm H<sub>2</sub>O)</p></td></tr><tr><td>Crude 90-day mortality</td><td>-31.6% vs. 40.7%, <italic>p</italic>&#x02009;=&#x02009;0.08</td><td>-42.5% vs. 42.8%; <italic>p</italic>&#x02009;=&#x02009;0.93</td></tr><tr><td>28-day mortality</td><td>-23.7% vs. 33.3%, <italic>p</italic>&#x02009;=&#x02009;0.05</td><td>-36.7% vs. 37.0%, <italic>p</italic>&#x02009;=&#x02009;NS</td></tr><tr><td>Ventilator induced lung injury</td><td><p>-Barotrauma: 5.1% vs. 11.7%; <italic>p</italic>&#x02009;=&#x02009;0.03</p><p>-Pneumothorax: 4.0% vs. 11.7%; <italic>p</italic>&#x02009;=&#x02009;0.01</p></td><td><p>-Barotrauma: 4.0% vs. 6.3%; <italic>p</italic>&#x02009;=&#x02009;0.12</p><p>-Pneumothorax: 2.8% vs. 5.0%; <italic>p</italic>&#x02009;=&#x02009;0.10</p></td></tr><tr><td>Other adverse effects</td><td>-None</td><td><p>-Serious cardiovascular events: NMBA14</p><p>vs. Control 4; <italic>p</italic>&#x02009;=&#x02009;0.02</p></td></tr></tbody></table><table-wrap-foot><p><italic>AECC</italic> American-European Consensus Conference, <italic>ARDS</italic> acute respiratory distress syndrome, <italic>TV</italic> tidal volume, <italic>PEEP</italic> positive end-expiratory pressure, <italic>NMBA</italic> neuromuscular blocking agent</p></table-wrap-foot></table-wrap></p><p id="Par5">The differences in study design and methodology best explain the varied results and any inference drawn; comparing these two trials would be misleading. In light of these recent findings, interest in the use of NMBAs might be tempered. NMBAs may have a role in ARDS management in the correct clinical context (refractory hypoxemia and recalcitrant ventilator dyssynchrony). Non-pharmacologic strategies centered around lung-protective ventilation and PEEP optimization should continue to be the backbone of ARDS management.</p></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>All authors helped write and edit the letter and read and approved the final letter.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>1. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. <italic>N Engl J Med</italic>. 2010; 363(12):1107&#x02013;1116.</p><p>2. Moss M, Huang DT, Brower RG, Ferguson ND, Ginde AA, Gong MN, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. <italic>N Engl J Med</italic>. 2019; 380(21):1997&#x02013;2008.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par6">Not applicable.</p></notes><notes><title>Consent for publication</title><p id="Par7">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par8">The authors declare they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhazzani</surname><given-names>W</given-names></name><name><surname>Alshahrani</surname><given-names>M</given-names></name><name><surname>Jaeschke</surname><given-names>R</given-names></name><name><surname>Forel</surname><given-names>JM</given-names></name><name><surname>Papazian</surname><given-names>L</given-names></name><name><surname>Sevransky</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Critical Care</source><year>2013</year><volume>17</volume><issue>2</issue><fpage>R43</fpage><pub-id pub-id-type="doi">10.1186/cc12557</pub-id><pub-id pub-id-type="pmid">23497608</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papazian</surname><given-names>L</given-names></name><name><surname>Forel</surname><given-names>JM</given-names></name><name><surname>Gacouin</surname><given-names>A</given-names></name><name><surname>Penot-Ragon</surname><given-names>C</given-names></name><name><surname>Perrin</surname><given-names>G</given-names></name><name><surname>Loundou</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neuromuscular blockers in early acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>12</issue><fpage>1107</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1005372</pub-id><pub-id pub-id-type="pmid">20843245</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellani</surname><given-names>G</given-names></name><name><surname>Laffey</surname><given-names>JG</given-names></name><name><surname>Pham</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>E</given-names></name><name><surname>Brochard</surname><given-names>L</given-names></name><name><surname>Esteban</surname><given-names>A</given-names></name><etal/></person-group><article-title>Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries</article-title><source>JAMA.</source><year>2016</year><volume>315</volume><issue>8</issue><fpage>788</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.0291</pub-id><pub-id pub-id-type="pmid">26903337</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>DT</given-names></name><name><surname>Brower</surname><given-names>RG</given-names></name><name><surname>Ferguson</surname><given-names>ND</given-names></name><name><surname>Ginde</surname><given-names>AA</given-names></name><name><surname>Gong</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Early neuromuscular blockade in the acute respiratory distress syndrome</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><issue>21</issue><fpage>1997</fpage><lpage>2008</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1901686</pub-id><pub-id pub-id-type="pmid">31112383</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Villar</surname><given-names>J</given-names></name></person-group><article-title>Early paralytic agents for ARDS? Yes, no, and sometimes</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><issue>21</issue><fpage>2061</fpage><lpage>2063</lpage><pub-id pub-id-type="doi">10.1056/NEJMe1905627</pub-id><pub-id pub-id-type="pmid">31112382</pub-id></element-citation></ref></ref-list></back></article>